BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

693 related articles for article (PubMed ID: 21724828)

  • 1. The diverse functions of Dot1 and H3K79 methylation.
    Nguyen AT; Zhang Y
    Genes Dev; 2011 Jul; 25(13):1345-58. PubMed ID: 21724828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The histone methyltransferase Dot1/DOT1L as a critical regulator of the cell cycle.
    Kim W; Choi M; Kim JE
    Cell Cycle; 2014; 13(5):726-38. PubMed ID: 24526115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The histone H3K79 methyltransferase Dot1L is essential for mammalian development and heterochromatin structure.
    Jones B; Su H; Bhat A; Lei H; Bajko J; Hevi S; Baltus GA; Kadam S; Zhai H; Valdez R; Gonzalo S; Zhang Y; Li E; Chen T
    PLoS Genet; 2008 Sep; 4(9):e1000190. PubMed ID: 18787701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DOT1L and H3K79 Methylation in Transcription and Genomic Stability.
    Wood K; Tellier M; Murphy S
    Biomolecules; 2018 Feb; 8(1):. PubMed ID: 29495487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The many faces of histone H3K79 methylation.
    Farooq Z; Banday S; Pandita TK; Altaf M
    Mutat Res Rev Mutat Res; 2016; 768():46-52. PubMed ID: 27234562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells.
    Steger DJ; Lefterova MI; Ying L; Stonestrom AJ; Schupp M; Zhuo D; Vakoc AL; Kim JE; Chen J; Lazar MA; Blobel GA; Vakoc CR
    Mol Cell Biol; 2008 Apr; 28(8):2825-39. PubMed ID: 18285465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes.
    Chang MJ; Wu H; Achille NJ; Reisenauer MR; Chou CW; Zeleznik-Le NJ; Hemenway CS; Zhang W
    Cancer Res; 2010 Dec; 70(24):10234-42. PubMed ID: 21159644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deficiency of H3K79 histone methyltransferase Dot1-like protein (DOT1L) inhibits cell proliferation.
    Kim W; Kim R; Park G; Park JW; Kim JE
    J Biol Chem; 2012 Feb; 287(8):5588-99. PubMed ID: 22190683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted disruption of the histone lysine 79 methyltransferase Dot1L in nephron progenitors causes congenital renal dysplasia.
    Wang F; Ngo J; Li Y; Liu H; Chen CH; Saifudeen Z; Sequeira-Lopez MLS; El-Dahr SS
    Epigenetics; 2021 Nov; 16(11):1235-1250. PubMed ID: 33315499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom).
    Mohan M; Herz HM; Takahashi YH; Lin C; Lai KC; Zhang Y; Washburn MP; Florens L; Shilatifard A
    Genes Dev; 2010 Mar; 24(6):574-89. PubMed ID: 20203130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The emerging roles of DOT1L in leukemia and normal development.
    McLean CM; Karemaker ID; van Leeuwen F
    Leukemia; 2014 Nov; 28(11):2131-8. PubMed ID: 24854991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of DOT1L in Normal and Malignant Hematopoiesis.
    Arnold O; Barbosa K; Deshpande AJ; Zhu N
    Front Cell Dev Biol; 2022; 10():917125. PubMed ID: 35712672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A medicinal chemistry perspective for targeting histone H3 lysine-79 methyltransferase DOT1L.
    Anglin JL; Song Y
    J Med Chem; 2013 Nov; 56(22):8972-83. PubMed ID: 23879463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conserved crosstalk between histone deacetylation and H3K79 methylation generates DOT1L-dose dependency in HDAC1-deficient thymic lymphoma.
    Vlaming H; McLean CM; Korthout T; Alemdehy MF; Hendriks S; Lancini C; Palit S; Klarenbeek S; Kwesi-Maliepaard EM; Molenaar TM; Hoekman L; Schmidlin TT; Altelaar AM; van Welsem T; Dannenberg JH; Jacobs H; van Leeuwen F
    EMBO J; 2019 Jul; 38(14):e101564. PubMed ID: 31304633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
    Chen CW; Koche RP; Sinha AU; Deshpande AJ; Zhu N; Eng R; Doench JG; Xu H; Chu SH; Qi J; Wang X; Delaney C; Bernt KM; Root DE; Hahn WC; Bradner JE; Armstrong SA
    Nat Med; 2015 Apr; 21(4):335-43. PubMed ID: 25822366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The upstreams and downstreams of H3K79 methylation by DOT1L.
    Vlaming H; van Leeuwen F
    Chromosoma; 2016 Sep; 125(4):593-605. PubMed ID: 26728620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dot1L mediated histone H3 lysine79 methylation is essential to meiosis progression in mouse oocytes.
    Wang X; Gao W; Ma X; Wang X; Song C; Huang X; Liu H
    Neuro Endocrinol Lett; 2014; 35(6):523-30. PubMed ID: 25433842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disruptor of telomeric silencing-1 is a chromatin-specific histone H3 methyltransferase.
    Lacoste N; Utley RT; Hunter JM; Poirier GG; Côte J
    J Biol Chem; 2002 Aug; 277(34):30421-4. PubMed ID: 12097318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond.
    Chen CW; Armstrong SA
    Exp Hematol; 2015 Aug; 43(8):673-84. PubMed ID: 26118503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A charge-based interaction between histone H4 and Dot1 is required for H3K79 methylation and telomere silencing: identification of a new trans-histone pathway.
    Fingerman IM; Li HC; Briggs SD
    Genes Dev; 2007 Aug; 21(16):2018-29. PubMed ID: 17675446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.